Home » Newsletters » BioWorld Science

BioWorld Science

June 20, 2014

View Archived Issues

Nymox reports nerve sparing and sexual preservation data on NX-1207

Pfizer and Cellectis establish cancer immunotherapy collaboration

Kyowa Hakko Kirin to begin a phase I trial of KHK-6640 for Alzheimer's disease

Flexion reports pharmacokinetic results for FX-006 in knee osteoarthritis

First data presented for ZP-GG-72, a dual GLP-1/2 agonist

Biosimilar infliximab BOW-015 shows equivalence in phase III trial

ProMetic completes phase I trial of PBI-4050

Protalix BioTherapeutics initiates phase II study of PRX-112

Zalicus licenses sodium channel pain modulation program to AnaBios

MRC Technology sells melanocortin receptor program to Pfizer

Janssen enters into license agreement with Vertex for influenza A treatment

Ziarco secures grant from U.K.'s Technology Strategy Board to advance ZPL-389

Asmacure discloses topline results of phase I/IIa trial of ASM-024 dry powder inhaler

Global ALS/MND Day news: Compounds with surprising effects in experimental ALS

Novel agents for cancer disclosed by Agios Pharmaceuticals

Researchers at AbbVie disclose novel PDE10A inhibitors

Portuguese group divulges agents for tuberculosis

Novartis patents new monophosphate prodrugs for viral infections

Merck & Co. designs novel gamma-secretase inhibitors

AT-13148 well tolerated in ongoing first-in-human study

Novel Ga-68 PET bone-targeting agent tested in vivo, ex vivo and in metastatic bone cancer patients

Sumitomo Dainippon Pharma approved as new English trade name

FDA accepts Cubist's NDA for ceftolozane sulfate/tazobactam sodium

Intec Pharma reports animal safety data for the Accordion Pill for carbidopa/levodopa

Sorafenib approved in Japan for thyroid carcinoma

Shire rejects acquisition proposal from AbbVie

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
Maintenance, man: Lilly’s phase III weight trial hits goals
BioWorld
Eli Lilly and Co. took another step toward adding a way for patients to hang onto their weight loss when the firm disclosed positive top-line data from the phase...